Journal Logo

Research Article: Observational Study

The investigation of CD4+T-cell functions in primary HIV infection with antiretroviral therapy

Sun, Yu MD; Fu, Yajing PhD; Zhang, Zining PhD; Tang, Tian BS; Liu, Jing MD; Ding, Haibo MD; Han, Xiaoxu PhD; Xu, Junjie PhD; Chu, Zhenxing MD; Shang, Hong PhD*; Jiang, Yongjun PhD*

Editor(s): Rosenthal., Ken S.

Author Information
doi: 10.1097/MD.0000000000007430
  • Open


1 Introduction

One feature of human immunodeficiency virus (HIV) infection is the major reduction in CD4+T-cell counts and immune dysfunction.[1,2] Previous studies have revealed that there is an imbalance in the distribution of the subsets of CD4+T cells, the levels of activation and senescence are increased, and the functions of CD4+T cells are impaired.[3–7] Administration of antiretroviral therapy (ART) can significantly reduce the HIV viral loads and restore the CD4+T-cell counts, improving the life expectancy of HIV-infected individuals.[6,8–11] Initiation of ART in HIV primary infection has been recommended to achieve an optimal clinical outcome, but a comprehensive study on CD4+T-cell functions still needs to be conducted. Although there are several studies assessing the recovery of CD4+T-cell counts, much less is known about the restoration of CD4+T-cell function during early ART (initiated within 6 months after HIV infection, determined by Fiebig stages, the last HIV-negative date and high-risk behavior).

The recovery of CD4+T-cell counts is the focus of investigation after ART. Previous studies revealed that CD4+T-cell counts were higher in those participants who initiated ART earlier in comparison with those initiated ART later.[12,13] The number of CD4+T cells is maintained by the balance between their production and destruction, that is, when destruction exceeds production, the CD4+T-cell counts declines.[14,15] Decelerated thymic emigrant function and an accelerated level of senescence may both lead to a reduction in the CD4+T-cell counts.[3,5,15] Thymic emigrant function is evaluated by the level of CD31+ naive T cells (CD31+TN) and T-cell senescence was characterized by expression of CD57, a surface marker indicating proliferative history and poor proliferative capacity.[5,16–18] Previous studies indicated thymic emigrant function and the senescence level could not be completely recovered even after ART was initiated in chronic HIV infection (CHI).[18,19] It remains unknown whether thymus dysfunction and/or abnormal senescence can be prevented in early ART. Meanwhile, chronically generalized activation is a major reason for the reduction in the CD4+T-cell counts in HIV infection,[20] and it also influenced the recovery of CD4+T-cell counts in HIV infection with ART.[21–23] The level of activation was reduced in patients receiving ART in CHI,[22,24] while it might remain high level of activation if immune reconstitution syndrome (IRS) happens usually in HIV-infected individuals with low mean CD4+T-cell counts before ART initiation.[3,25] It was reported that early ART was associated with a reduced degree of T-cell activation, but the activation level still remained higher compared to HIV-negative controls.[13,21,26] The kinetic changes in the CD4+T-cell activation level and activation of CD4+T-cell subsets in patients receiving early ART have been less extensively investigated. In addition to the changes in the CD4+T-cell counts, HIV infection causes CD4+T-cell function damage.[7] Previous studies indicated that later ART (initiated more than 12 months after HIV infection) may partially restore CD4+T-cell function,[27,28] but the proliferative function and interferon-γ (IFN-γ) secretory function of CD4+T cells in early ART have rarely been reported.

The aim of this study was to determine whether early ART has a better role in recovery of T-cell functions compared with later ART, and we explored the restoration of CD4+T-cell counts, the reversal of CD4+T-cell abnormal activation, senescence, and dysfunction. Our data indicated that early ART played an important role in restoration of CD4+T-cell functions, but thymic emigrant function cannot be restored.

2 Methods

2.1 Subjects

HIV-infected persons from the First Hospital of China Medical University were recruited and subdivided into 4 groups: primary HIV infection group (PHI, 82 participants) which was defined as persons infected with HIV for less than 6 months without receiving ART; CHI group (101 participants) which was defined as untreated subjects who had been infected with HIV for more than 1 year; early ART group (early ART, 45 participants) which was defined as patients initiated ART within the first 6 months after HIV infection; and later ART group (later ART, 83 participants) which was defined as patients initiated ART more than 12 months after HIV infection. The infection day was estimated by an integrated analysis of fiebig stages (determined by HIV viral ribonucleic acid, HIV specific antibody, and p24 antigen), last negative date and their high-risk behavior. All subjects of this study decided when to initiate therapy by themselves. All patients were treated with regimens including 2 nucleoside reverse transcriptase inhibitors as backbone, and 1 nonnucleoside reverse transcriptase inhibitor was added in 40 patients (88.9%) in early ART and 80 patients (96.4%) in later ART, or 1 protease inhibitors was added in 5 patients (11.1%) in early ART and 3 patients (3.6%) in later ART. At the time of sample collection, patients from early ART and later ART groups had received ART for at least 1 year, with viral loads less than 20 copies/mL. Thirty-one HIV-negative healthy participants were chosen to be the normal controls (NC) (Table 1).

Table 1
Table 1:
Characteristics of participants.

We provided written informed consent to each participant in the study. Our study was approved by the Research and Ethics Committee of The First Hospital of China Medical University. The whole process of the study was conducted according to the principles of the Declaration of Helsinki.

2.2 Antibodies used for flow cytometry

Anti-CD3-PE-cy7, anti-CD45RA-FITC, anti-CD3-FITC/CD8-PE/CD45-PerCP/CD4-APC, and anti-CD38-PE reagents were purchased from BD Biosciences (San Jose, CA). Anti-CD4-APC-cy7, anti-CCR7-PerCP-cy5.5, anti-human leukocyte antigen DR-APC, and anti-IFN-γ-APC reagents were purchased from BD PharMingen (San Diego, CA). Anti-CD31-APC and anti-CD57-PE were purchased from BioLegend (San Diego, CA). Anti-CCR7-APC was purchased from R&D Systems (Minneapolis, MN).

2.3 Measurement of absolute CD4+T-cell counts and plasma viral loads

A single-platform lyse-no-wash procedure was performed with TruCOUNT tubes (BD Biosciences) and anti-CD3-FITC/CD8-PE/CD45-PerCP/CD4-APC reagent (BD Biosciences). CD4+T-cell counts were analyzed by a FACS Calibur flow cytometer (BD Biosciences) and MultiSET software (BD Biosciences, San Jose, CA).

Plasma Viral Loads were detected by reverse transcriptase polymerase chain reaction with the COBAS Amplicor HIV Monitor 1.5 (Roche Molecular Systems, Branchbury, NJ). Undetectable limitation was defined as plasma viral loads <20 copies/mL.

2.4 Immunostainings of T-cell subsets

Fresh whole blood samples were stained using fluorochrome-conjugated antibodies, and we determined the T-cell subsets, defined as naive T cells (TN, CD45RA+CCR7+), effector memory T cells (TEM, CD45RA+CCR7), and central memory T cells (TCM, CD45RACCR7+). HLA-DR and CD38 were used to determine the activation of T cells. The phenotypes of T cells were detected by flow cytometry (LSRII; BD Biosciences) and analyzed with BD FACSDiva software (BD Biosciences, San Jose, CA).

2.5 Proliferation assays

Fresh peripheral blood mononuclear cells (PBMC) were labeled with the CellTrace carboxyfluorescein diacetate succinimidyl ester (CFSE) Cell Proliferation Kit (Invitrogen, Carlsbad, CA) at a final concentration of 2 μmol/L in serum-free RPMI 1640 (Hyclone, Logan, UT) for 15 minutes at 37 °C in 5% CO2. Stained cells (2 × 106 cells/mL) were incubated with anti-CD3 (0.5 μg/mL, BD Biosciences) and anti-CD28 (1 μg/mL, BD Biosciences) in R-10 medium (RPMI 1640 supplemented with 10% fetal bovine serum) for 5 days. On day 5, cells were stained with anti-CD3-PE-cy7 and anti-CD4-APC-cy7 and detected by flow cytometry.

2.6 Intracellular cytokine staining

Fresh PBMC (2.5 × 106 cells/mL) were incubated with anti-CD28 (2 μg/mL) and anti-CD3 (1 μg/mL) for 18 hours, then Golgi stop (BD PharMingen) was added and incubated for an additional 6 hours. The cells were stained with anti-CD3-PE-cy7 and anti-CD4-APC-cy7, then permeabilized with Cytofix/Cytoperm (BD PharMingen) for 30 minutes and stained with anti-IFN-γ-APC (BD PharMingen). Cells were detected by flow cytometry.

2.7 Statistical analysis

Statistical analyses were performed using SPSS 17.0. Mann–Whitney U was used to compare between 2 groups of subjects. The Kruskal–Wallis and Mann–Whitney U tests were used to compare among the multiple groups of subjects. All tests were 2-tailed, and P < .05 was considered significant.

3 Results

3.1 Trajectories of CD4+T-cell counts during early ART and later ART

To investigate whether the recovery of CD4+T-cell counts was better in early ART, we examined the kinetic changes of CD4+T-cell counts both in early ART and later ART. After 30 months of ART, CD4+T-cell counts of all the 78 patients increased from 243 to 413 cells/μL. The elevation in CD4+T-cell counts was most prominent during the first 3 months after ART initiation (mean change 136 cells/μL). After the first 3 months, CD4+T-cell counts became relatively stable (Fig. 1A).

Figure 1
Figure 1:
Trajectories of CD4+T-cell counts during early antiretroviral therapy (ART) and later ART. (A) Trajectory of CD4+T-cell counts in patients with ART (n = 78, mean values ± standard deviation (SD) are shown in the figure). (B) Trajectories of CD4+T-cell counts in individuals initiating ART ≤ 6 months of infection (early ART, red, n = 33), or ≥1 years after initial infection (later ART, blue, n = 45, mean values are shown in figure). (C) Monthly changes of CD4+T-cell counts (ΔCD4+T/month) were compared between early ART (red, n = 33) and later ART (blue, n = 45) (mean values ± SD are shown in figure). Contribution of individuals with different CD4+T-cell changes (ΔCD4+T) to the overall total after 12 months of early ART (D) or later ART (E). * P < .05, ** P < .01.

Compared with later ART, CD4+T-cell counts in early ART were always higher (Fig. 1B). Monthly changes of CD4+T-cell count from baseline (△CD4+T/month) in early ART were higher than those in later ART during the 1st month (143 ± 142 vs 82 ± 73 cells/μL, P = .012); in addition, at the 3rd and 12th month, △CD4+T/month count in the early ART were significantly higher than those in later ART (57 ± 44 vs 37 ± 24 cells/μL, P = .011; 18 ± 12 vs 12 ± 9 cells/μL, P = .008) (Fig. 1C).

Furthermore, after 12 months of ART, patients with CD4+T-cell counts change from baseline (△CD4+T) greater than 300 cells/μL, were observed in 33% of the early ART cases but only 9% in those with later ART; in contrast, △CD4+T less than 100 cells/μL were detected in 21% of the early ART cases but almost double that number (38%) when the ART was initiated later (Fig. 1D and E). In summary, individuals with ART that had been initiated in the primary stage had not only a greater CD4+T-cell count, but also a faster rate of CD4+T-cell recovery than those in whom ART started later.

3.2 Early ART restores more CD4+TN cells

In addition to cell count, another important factor that contributes to CD4+T-cell functioning is the subset construction. We analyzed the CD4+T-cell subsets in patients receiving either early or later ART. By using CD45RA and CCR7, 3 CD4+T-cell subsets could be identified in human peripheral blood samples: TN, TEM, and TCM (Fig. 2A). The percentage of CD4+TN in early ART was higher than that observed in later ART (P = .023), and it was similar to the situation in NC, and the percentage of CD4+TN in later ART and CHI were lower than those detected in the NC (P = .001; P = .04, respectively); in comparison with CHI, CD4+TN in PHI was higher (P = .036) (Fig. 2B). The percentage of CD4+TEM in CHI was higher than the corresponding values in PHI and NC (P = .013; P = .003, respectively), and the percentage of CD4+TEM in the early ART was not different from the NC; however, the percentage of CD4+TEM in later ART was higher than that in NC (P = .003) (Fig. 2D). The percentage of CD4+TCM in later ART was higher than the corresponding values in CHI and NC (P = .003; P = .047, respectively) (Fig. 2C). HIV-infected individuals receiving early ART had higher CD4+TN values and lower CD4+TEM in comparison with later ART.

Figure 2
Figure 2:
Percentage of CD4+T-cell subsets and CD31+CD4+ naive T cell (TN) counts in patients receiving early antiretroviral therapy (ART) or later ART. (A) The gating strategy involved a FS-SS gate for lymphocytes, CD3+CD4+ gate for CD4+T cells; CD45RA+CCR7+ gate for naive CD4+T cell (TN); CD45RACCR7+ and CD45RACCR7 gates for central memory and effector memory T cells. The percentages of CD4+T subsets naive (B), central memory T cell (C), and effector memory T cell (D) were detected by flow cytometry (LSRII; BD Biosciences) and analyzed with BD FACSDiva software. The data are presented for all 5 groups: HIV-negative normal controls (NC, yellow, n = 21), primary HIV infections (PHI, red, n = 43), early ART (early ART, green, n = 15), chronic HIV infections (CHI, blue, n = 42), and later ART (later ART, purple, n = 20). Thymic emigrant function was determined by measuring absolute count of CD31+CD4+TN (E) in NC (n = 19), PHI (n = 31), early ART (n = 11), CHI (n = 21), and later ART (n = 17). Horizontal lines represent mean values. * P < .05, ** P < .01.

3.3 Early ART preserves higher thymic emigrant function

The thymus is the major source of CD4+TN. We studied the thymic emigrant function of those patients receiving either early or later ART, by determining the expression of CD31 on CD4+TN. In comparison with the NC, the CD31+CD4+TN counts were lower in the following groups: early ART, later ART, PIH, and CHI (P = .027; P < .001; P = .005; P < .001, respectively); CD31+CD4+TN counts were higher in PHI when compared with CHI (P = .038); CD31+CD4+TN counts in early ART were higher than in later ART (P = .015) (Fig. 2E). This indicated that early ART may achieve better thymic emigrant function than later ART, but the improvement was still lower than the value in NC.

3.4 Early ART causes lower activation of CD4+T cells

To investigate the different changes of the activation level of CD4+T cells in patients with early ART compared with later ART, we assessed the kinetic changes in CD4+T-cell activation in these 2 group. During 12 months of ART, the activation (HLA-DR+CD38+) of CD4+T was decreased in individuals receiving either early ART or later ART. The decline in activation occurred most prominently during the first 3 months after ART; this was the case in both early and later ART, after that time, the change started to stabilize. Importantly, the activation of CD4+T cells in early ART was always lower than those occurring in later ART (Fig. 3A).

Figure 3
Figure 3:
CD4+T-cell activation status with early antiretroviral therapy (ART) or later ART. Activation of CD4+T cell was evaluated by HLA-DR and CD38. (A) Trajectory of activation of CD4+T cell in patients with early ART (red, n = 24) or later ART (blue, n = 25). We evaluated the activation level at baseline (0), 3, 6, 12 months since initiation of ART. (B) Activation status was determined in total CD4+T cells (normal controls [NC], n = 21; primary HIV infection (PHI), n = 55; early ART, n = 18; chronic HIV infection (CHI), n = 40; Later ART, n = 25). The level of activation was evaluated in CD4+ central memory T cell (C) and CD4+ effector memory T cell (D) (NC, n = 21; PHI, n = 34; early ART, n = 9; CHI, n = 26; Later ART, n = 19). Horizontal lines represent mean values. * P < .05, ** P < .01.

The activation of CD4+T cells was higher in the PHI and CHI groups as compared to NC (P < .001; P < .001); the CD4+T-cell activation status in early ART and later ART was lower than those in PHI and CHI. (early ART vs PHI: P < .001; later ART vs CHI: P = .001), but still higher than NC (early ART vs NC: P = .001; later ART vs NC: P < .001); the level of CD4+T-cell activation was lower in early ART in comparison to the situation in patients receiving later ART (P = .031) (Fig. 3B). We further tested the activated levels of CD4+T-cell subsets, and it showed the similar results (Fig. 3C and D). This indicated that individuals receiving early ART had a lower activation level of CD4+T cells than in later ART, but the value remained higher than in NC.

3.5 Reduced senescence of CD4+T cell in early ART

We measured the expression of CD57 molecule to evaluate senescence of CD4+T cells in HIV-infected individuals. The percentage of CD57+CD4+T cell was higher in CHI than in 3 other groups that is, later ART, PHI, and NC (P = .01; P < .001; P < .001, respectively), and the percentages of CD57+CD4+T cell in early ART were lower than those in later ART (P = .016) (Fig. 4A). We further tested the senescence of CD4+T-cell subsets, and it showed the similar results (Fig. 4B). Thus, the senescence of CD4+T cell was reduced in patients with early ART in comparison with the later ART group.

Figure 4
Figure 4:
CD4+T-cell senescence status in patients receiving either early antiretroviral therapy (ART) or later ART. CD57 was used to characterize senescent status of the CD4+T cells. Percentages of CD57 were determined in CD4+T cells (A) (normal controls [NC], n = 19; primary HIV infection [PHI], n = 39; Early ART, n = 11; chronic HIV infection (CHI), n = 23; Later ART, n = 24) and CD4+ effector memory T cell (B) (NC, n = 19; PHI, n = 32; Early ART, n = 11; CHI, n = 23; Later ART, n = 18). Horizontal lines represent mean values. * P < .05, ** P < .01.

3.6 Early ART improves the proliferative capacity of CD4+T cells

In addition to the counts and phenotype of CD4+T cell, we studied whether therapy initiated at different time exerted different effects on the recovery of CD4+T-cell functions. We used CFSE to determine proliferative capacity and used CFSElow to reflect CD4+T-cell proliferation (Fig. 5A). The percentages of proliferating CD4+T cells in PHI group, CHI group, and later ART group were lower than those in NC (P < .001; P = .001; P = .005, respectively), and the percentage of proliferating CD4+T cell was higher in individuals with early ART than in either PHI or later ART (P = .002; P = .037) (Fig. 5B). It is concluded that proliferative capacity of CD4+T cells was better in early ART in comparison with later ART.

Figure 5
Figure 5:
Proliferation capacity of CD4+T cells. Carboxyfluorescein diacetate succinimidyl ester (CFSE) was used to determine the proliferation capacity of CD4+T cells. (A) Representative flow cytometric plots showed the proliferative capacity of CD4+T cells in normal controls (NC), primary HIV infection (PHI), early antiretroviral therapy (ART), chronic HIV infection (CHI), and later ART. Peripheral blood mononuclear cells stained with CFSE were incubated with anti-CD3 and anti-CD28 for 5 days. The CFSElow gate was used to determine proliferative CD4+T cells. (B) The percentages of proliferative CD4+T cells in 5 groups. (NC, n = 6; PHI, n = 9; Early ART, n = 6; CHI, n = 8; Later ART, n = 11). Horizontal lines represent mean values. * P < .05, ** P < .01.

IFN-γ secretion is another important function for some CD4+T cells. In comparison with the NC, the percentages of IFN-γ secreting CD4+T cells were lower in the following groups: PHI group, CHI group, and later ART group (P = .029; P = .023; P = .019, respectively), and the percentage of IFN-γ secreting CD4+T was higher in early ART when compared with PHI (P = .038), but not significantly different from the NC (Fig. 6A and B). It is concluded that the secretory capacity of CD4+T cells in the early ART group was better than those in later ART.

Figure 6
Figure 6:
Cytokine secretion of CD4+T cell. (A) Representative flow cytometric plots illustration the interferon-γ (IFN-γ) secretion in CD4+T cells between normal controls (NC), primary HIV infection (PHI), early antiretroviral therapy (ART), chronic HIV infection (CHI) and Later ART. (B) The percentages of IFN-γ secretion in CD4+T cells in 5 groups (NC, n = 4; PHI, n = 4; Early ART, n = 6; CHI, n = 7; Later ART, n = 6). Horizontal lines represent mean values. * P < .05, ** P < .01.

4 Discussion

The decline of CD4+T-cell counts is the most prominent and representative feature of HIV infection and an elevated CD4+T-cell counts is known to be a critical factor in immune recovery.[12,29,30] Our data showed that CD4+T-cell counts in patients receiving early ART were always higher than those in whom ART was initiated later. This is consistent with recent studies,[1,31–33] but we further found early ART may restore more percentage of TN than later ART, quite different from the study of Amu et al[34], which showed a similar level of CD4+T-cell counts and the percentage of TN between early and later ART. The reason for these differences between the 2 studies is possibly due to the CD4+T-cell counts at initiation of later ART is higher than that in early ART in Amu et al study.

The restoration of CD4+T-cell counts may be quite related with initial CD4+T-cell counts. In order to remove this bias, we detected the monthly changes of CD4+T-cell counts (△CD4+T/month) and CD4+T-cell growth after 12 months of ART (△CD4+T). As far as we are aware, this type of calculation has not been previously reported in early ART. We found that △CD4+T/month and △CD4+T were also higher in patients with early ART than in those receiving later ART. This indicated that early ART was more efficient than later ART in promoting the recovery of the CD4+T-cell counts. PHI was regarded as “restorative time window,” that is, a time when the immune system could be strategically poised for recovery.[12,35,36] Therefore, it represents a good opportunity for initiating ART to improve the chances that the immune system can optimally be restored.

Part of the reason for the recovery of CD4+T-cell counts may be due to thymic emigrants function. The thymus represents the major site of the production and generation of CD4+T cells, and thus its function affects the number and constitution of CD4+T cells during HIV infection.[5] For example, decreased thymic function might result in the failure to restore circulating CD4+T cells after the control of HIV replication with ART. Our data showed that HIV-infected patients with early ART had better thymic emigrant function than those with later ART. Nonetheless, the early ART patients still exhibited lower thymic emigrant function than NC, and in fact, there was no difference in this property between primary/CHI with or without therapy. We conclude that thymic emigrant function becomes damaged during the primary stage of HIV infection, and once damaged, it is difficult to be restored. Therefore, ideally HIV-infected individuals should be identified and encouraged to initiate ART as soon as possible, in order to avoid the destruction of thymic function.

HIV infection evoked a generalized activation of the immune system, and a higher level of T-cell activation has been associated with a reduced recovery of the CD4+T-cell counts, increased mortality, and cardiovascular diseases.[16,21–23,37–40] Abnormal activation can increase HIV replication promote cell apoptosis, accelerate cell senescence, and cellular exhaustion, and it has also been associated with the HIV reservoir size.[41–43] We observed that although the activation of CD4+T cells was less intensive in individuals with early ART than in those receiving later ART, it still remained elevated when compared with NC. It is consistent with previous studies that is, early ART may help reduce the level of T-cell activation.[13,21] We further tested the activation of CD4+T-cell subsets; it was observed that the CD4+TCM activation level was lower in early ART compared with later ART. As it is known that CD4+TCM is an important component of the viral reservoir,[35] 1 could speculate that the lower degree of activation may have decreased the HIV reservoir size by impairing HIV-1 DNA replication. We also found higher frequency and activation of CD4+TEM in patients with later ART. A possible reason for those elevation could be attributed to IRS, which usually takes place in chronic HIV-infected individuals with CD4+T-cell lymphopenia before ART initiation. After the restoration of CD4+T cells, bacterial and viral infections may result in the expansion of the effector memory T cells and lead to remarkable T-cell activation.

Immune activation and chronic inflammatory are thought to drive T-cell senescence.[2,44,45] The expression of CD57 is frequently used as a biological marker of T-cell senescence.[46,47] Previous studies revealed that the senescence of CD8+T cell can be reversed with early ART initiation.[16,48] We observed less senescence of CD4+T cell in early ART compared with later ART; furthermore, the data showed that there was no significant difference in the level of senescence of the CD4+T cells between primary infection with/without ART and NC. Our data also indicated that the percentage of senescent CD4+T cells was higher in patients with CHI, became decreased in later ART, but still remained higher in comparison with early ART. In summary, although later ART can reduce CD4+T-cell senescence, early ART is more efficacious in this respect.

In addition to the improvement of CD4+T-cell counts and phenotypes, a recovery of immune functions is also very important. Our results revealed the impaired proliferation capacity and reduced IFN-γ secretion of CD4+T cells in HIV-infected patients; early ART restored these CD4+T-cell functions, but if the ART was provided later, then there was only a partial recovery of the functions of CD4+T cells, that is, it still remained lower than that of NC. The restored proliferative capacity is related to the recovery of CD4+T-cell counts and IFN-γ secretion play an important role as it possesses antiviral, antitumor, and antimicrobial properties. We conclude that HIV-infected individuals should receive ART during the primary phase of the infection to promote the recovery of immune functions.

Our study has some limitations. First, initial CD4+T-cell counts were not matched between early ART and later ART, because it was difficult to find higher initial CD4+T-cell counts in later ART. Second, because of the limitation of blood collection at 1 time, we examined a relatively small number of cases in the experiments assessing CD4+T-cell functions. Third, our study was not a randomized clinical trial, the subjects decided for themselves whether and when to initiate ART.

5 Conclusion

Our data demonstrated that early ART confers not only quantitative but also qualitative benefits for CD4+T-cell reconstitution. The greater CD4+T counts, faster rate of CD4+T-cell recovery, lower immune activation and immune cell senescence, better proliferative capacity and IFN-γ secretion of CD4+T cells and restored thymic emigrants function were all associated with early ART and it was superior to later ART. Therefore, initiation of early ART could significantly promote immune functions of CD4+T cells.


The authors wish to express their gratitude to those patients who participated in this study.


[1]. Cao W, Mehraj V, Trottier B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis 2016;62:250–7.
[2]. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013;39:633–45.
[3]. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008;214:231–41.
[4]. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751–6.
[5]. Rickabaugh TM, Kilpatrick RD, Hultin LE, et al. The dual impact of HIV-1 infection and aging on naive CD4 T-cells: additive and distinct patterns of impairment. PLoS One 2011;6:e16459.
[6]. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361–72.
[7]. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989;84:1892–9.
[8]. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011;25:2069–78.
[9]. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010;24:614–7.
[10]. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441–6.
[11]. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293–9.
[12]. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368:218–30.
[13]. Cao W, Mehraj V, Vyboh K, et al. Antiretroviral therapy in primary HIV-1 infection: influences on immune activation and gut mucosal barrier dysfunction. AIDS Rev 2015;17:135–46.
[14]. Gaardbo JC, Hartling HJ, Ronit A, et al. Different immunological phenotypes associated with preserved CD4+ T cell counts in HIV-infected controllers and viremic long term non-progressors. PLoS One 2013;8:e63744.
[15]. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev 2013;254:54–64.
[16]. Lee SA, Sinclair E, Jain V, et al. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 2014;210:374–82.
[17]. Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012;9:e1001194.
[18]. Lu I, Eberhard J, Ahmad F, et al. Elevated CD57 and CD95 expressions are associated with lower numbers of CD4(+) recent thymic emigrants in HIV-1 infected immune responders following antiretroviral treatment. Immunol Lett 2014;158:1–6.
[19]. Cobos Jimenez V, Wit FW, Joerink M, et al. T-cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment. J Infect Dis 2016;214:216–25.
[20]. Moanna A, Dunham R, Paiardini M, et al. CD4+ T-cell depletion in HIV infection: killed by friendly fire? Curr HIV/AIDS Rep 2005;2:16–23.
[21]. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013;208:1202–11.
[22]. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003;187:1534–43.
[23]. Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006;42:426–34.
[24]. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–6.
[25]. Hirsch HH, Kaufmann G, Sendi P, et al. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159–66.
[26]. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 2013;62:505–8.
[27]. Li TS, Tubiana R, Katlama C, et al. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682–6.
[28]. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003;17:2015–23.
[29]. Zeng M, Haase AT, Schacker TW. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol 2012;33:306–14.
[30]. Zeng M, Southern PJ, Reilly CS, et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog 2012;8:e1002437.
[31]. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013;368:218–30.
[32]. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014;10:e1004078.
[33]. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013;68:1169–78.
[34]. Amu S, Lantto Graham R, Bekele Y, et al. Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection. Medicine (Baltimore) 2016;95:e3738.
[35]. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 2014;88:10056–65.
[36]. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194:725–33.
[37]. Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006;194:29–37.
[38]. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011;203:452–63.
[39]. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis 2011;217:207–13.
[40]. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011;25:2123–31.
[41]. Hurst J, Hoffmann M, Pace M, et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun 2015;6:8495.
[42]. Klatt NR, Chomont N, Douek DC, et al. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013;254:326–42.
[43]. Cockerham LR, Siliciano JD, Sinclair E, et al. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One 2014;9:e110731.
[44]. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51–9.
[45]. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011;53:1120–6.
[46]. Vivar N, Ruffin N, Sammicheli S, et al. Survival and proliferation of CD28− T cells during HIV-1 infection relate to the amplitude of viral replication. J Infect Dis 2011;203:1658–67.
[47]. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003;101:2711–20.
[48]. Sandler NG, Zhang X, Bosch RJ, et al. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014;210:1549–54.

CD4+T-cell function; early ART; HIV infection; later ART

Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.